BrainStorm Cell Therapeutics recently released results of a study of NurOwn in patients with Amyotrophic Lateral Sclerosis (ALS) that found NurOwn was safe and well-tolerated with clear evidence of clinically meaningful benefit.
"We are very encouraged by these Phase 2 data that show that NurOwn cell therapy is safe and that a single administration produces a transient and clinically meaningful beneficial response in terms of both the ALS-FRS-R rating scale and CSF biomarkers," Robert Brown, professor and chair of neurology at the University of Massachusetts Medical Center and Medical School, said. "These exciting findings clearly indicate that it is appropriate to conduct a longer study with repetitive dosing."
The study was conducted as a randomized, double-blind, placebo controlled, phase 2 study on 48 people affected by ALS in the U.S.
"After almost thirty years of conducting clinical studies in ALS I am personally very encouraged and excited by the trial results." Anthony Windebank professor of neurology, said. "There are positive efficacy signals with clear indications to proceed to the next phase. We at Mayo clinic will be eager to move ahead with that as soon as possible."
Organizations in this story
BrainStorm Cell Therapeutics Inc. 3 University Plaza Dr Hackensack, NJ 07601
- Montana lawmakers preserve private-road rights
- Nevada cautions horse owners after reports of EHV-4, strangles
- American Farm Bureau Federation outlines concerns at USDA forum
- Kansas looks for beef trade mission participants
- Project to introduce drought-resistant maize continues in Africa
- American Soybean Association outlines its concerns on Farm Bill
- Commodity Classic set to kick off in San Antonio
- Second-graders enjoy a day of 'Ag Venture'
- Florida offers potentially life-saving app
- Connecticut hopes third time's a charm for conservationists